LISATA THERAPEUTICS, INC. 8-K

What Happened

• Lisata Therapeutics, Inc. (LSTA) announced it terminated the Agreement and Plan of Merger with Kuva Labs Inc. and its subsidiary Kuva Acquisition Corp. (the Merger Agreement) pursuant to Section 8.3(a). The tender offer expired one minute after 11:59 p.m. (New York City Time) on July 20, 2026, and Parent/Purchaser failed to accept for payment all shares validly tendered. Kuva informed Lisata it was unable to obtain sufficient financing to fund the Offer and will direct the depositary (Equiniti Trust Company, LLC) to return tendered shares to holders.

Key Details

• Offer terms (previously announced): $4.00 cash per common share plus one contingent value right (CVR) representing up to $3.00 in milestone-based contingent payments (total possible consideration up to $7.00 per share).
• Termination consequence: Parent is obligated to pay Lisata a $2,000,000 termination fee under the Merger Agreement.
• Lisata reserves rights to pursue legal remedies (including damages for “Willful Breach” and enforcement costs), but noted potential limits on recovery due to its own limited resources and Kuva/Purchaser’s possible inability to satisfy any judgment.

Why It Matters

• The merger collapse returns tendered shares to holders and ends the proposed $4 cash + CVR transaction; investors should note the immediate contractual $2.0M termination fee is payable but recovery of additional damages is uncertain.
• Lisata’s Board will now conduct a strategic review of options to enhance shareholder value—examples listed include a reverse merger, other business combinations, asset sales, dissolution, or other transactions—but there is no timetable and no assurance this process will produce any transaction.
• For investors, this filing is material because it ends a near-term path to a deal and begins a period of strategic uncertainty; the potential cash inflow from the termination fee and any future strategic outcome may affect company prospects, but the company provided no forecast or timeline.